|Table of Contents|

Immune-related thyroid dysfunction associated with therapeutic efficacy and survival in gastric cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 16
Page:
3037-3041
Research Field:
Publishing date:

Info

Title:
Immune-related thyroid dysfunction associated with therapeutic efficacy and survival in gastric cancer
Author(s):
LIU Chunhui; WANG Peihong; TANG Yong
Department of Gastroenterology,Cancer Hospital Affiliated to Xinjiang Medical University，Xinjiang Urumqi 830000，China.
Keywords:
advanced gastric cancer; immune-related thyroid dysfunction; efficacy; survival analysis
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2023.16.017
Abstract:
Objective：To analyze the occurrence and outcome of immune-related thyroid dysfunction in the treatment of advanced gastric cancer,and to study its relationship with efficacy and prognosis.Methods：We retrospectively analyzed the data of patients with first-diagnosed advanced gastric cancer who presented to department of gastroenterology in our hospital from January 2019 to January 2022 for chemotherapy combined with immunosuppressive agents.The occurrence and outcome of thyroid dysfunction were recorded.The clinical efficacy,progression-free survival (PFS) and 1-year overall survival (OS) rates were compared between immune-related thyroid dysfunction (IrTD) group and non-immune-related thyroid dysfunction (N-IrTD) group.Results：Immune-related thyroid dysfunction developed in 26 of 72 patients (36.11%),with a median time to onset of 12.4 weeks (6.1~16.5 weeks).Most thyroid dysfunction was self-limiting or improved with medical intervention and was asymptomatic or minimally symptomatic and did not require interruption or discontinuation of immunotherapy.The objective remission rate (ORR) in IrTD group was significantly higher than that in N-IrTD group (65.38% vs 32.61%,P＜0.01).The 1-year OS rate in IrTD group was higher than that in the N-IrTD group (69.23% vs 43.48%,P＜0.05).K-M curve analysis showed that median PFS was prolonged by 1.99 months (8.12 months vs 6.13 months,HR=0.585,95%CI:0.352~0.973) in the IrTD group compared with the N-IrTD group (P＜0.05).Conclusion：Immune-related thyroid dysfunction is a common immune-related adverse events (irAEs),which is safe and controllable and may be associated with better efficacy and survival benefits.

References:

[1] SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
[2] 周家琛,郑荣寿,王少明,等.2020年中国和世界部分国家主要消化道肿瘤负担比较［J］.肿瘤综合治疗电子杂志,2021,7(2):26-32. ZHOU JC,ZHENG RS,WANG SM,et al.Comparison of the burden of major gastrointestinal tumors between China and some countries in the world in 2020［J］.Electronic Journal of Comprehensive Cancer Therapy,2021,7(2):26-32.
[3] LIMA FERREIRA J,COSTA C,MARQUES B,et al.Improved survival inpatients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors［J］.Cancer Immunology,Immunotherapy:CII,2021，70(2)：299-309.
[4] YOON JH,HONG AR,KIM HK,et al.Characteristics of immune-related thyroid adverse events in patients treated with PD-1/PD-L1 inhibitors［J］.Endocrinology and Metabolism (Seoul,Korea),2021，36(2):413-423.
[5] SAKAKIDA T,ISHIKAWA T,UCHINO J,et al.Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade［J］.Oncology Letters,2019,18(2):2140-2147.
[6] KOTWAL A,RYDER M.Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers［J］.Current Opinion inEndocrinology,Diabetes,and Obesity,2021,28(5):517-524.
[7] CHILELLI MG,SIGNORELLI C,GIRON BERRIOS JR，et al.Immune-related thyroid dysfunction (irTD) in non-small cell lung cancer (NSCLC) correlates with response and survival［J］.Cancer Diagnosis & Prognosis,2022,2(1):55-63.
[8] IWAWA S,KOBAYASHI T,YASUDA Y,et al.Immune checkpoint inhibitor-related thyroid dysfunction［J］.Best Practice & Research.Clinical Endocrinology & Metabolism,2022,36(3):101660.
[9] IZAWA N,SHIOKAWA H,ONUKI R,et al.The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors:a retrospective study［J］.ESMO Open,2022,7(2):100415.
[10] 宫雯雯,周枫叶,郭清华.程序性死亡受体1抑制剂相关性甲状腺损伤的临床特征和相关因素分析［J］.中华内科杂志,2023,62(2):176-181. GONG WW,ZHOU FY,GUO QH.Clinical characteristics and risk factors of programmed death-1 inhibitors associated with thyroid gland injury［J］.Chinese Journal of Internal Medicine,2023,62(2):176-181.
[11] CHEUNG YM,WANG W,MCGREGOR B,et al.Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors:a systematic review and meta-analysis［J］.Cancer Immunology,Immunotherapy:CII,2022,71(8):1795-1812.
[12] OLSSON-BROWN A,LORD R,SACCO J,et al.Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction［J］.Endocrine Connections,2020,9(4):318-325.
[13] VON ITZSTEIN MS,GONUGUNTA AS,WANG Y,et al.Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors.［J］Cancer Immunology,Immunotherapy:CII,2022,71:2169-2181.
[14] PADERI A,GIORGIONE R,GIOMMONI E,et al.Association between immune related adverse events and outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors［J］.Cancers (Basel):2021,13(4):860.

Memo

Memo:
-
Last Update: 1900-01-01